Lancelotta R

Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, Columbus, OH, USA.

18 papers · ORCID

ArticlePsilocybin

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial.

Armstrong SB, Levin AW, Sepeda ND +5

Europe PMC2026
ArticleDMT

Correction to: Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.

Uthaug MV, Lancelotta R, Szabo A +3

Europe PMC2026
ArticleMDMA

Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study.

Lancelotta R, DellaCrosse M, Quinn D +7

Europe PMC2025
ArticlePsychedelics

Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people.

Gaughan SJ, Wootton AR, Krantz D +5

Europe PMC2025
ArticlePsilocybin

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.

Levin AW, Lancelotta R, Sepeda ND +6

Europe PMC2024
ArticlePsilocybin

Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.

Davis AK, Timmermann C, Ortiz Bernal AM +5

Europe PMC2024
ArticlePsychedelics

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

Nikolaidis A, Lancelotta R, Gukasyan N +3

Europe PMC2023
ArticleAyahuasca

5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous.

Lancelotta R

Europe PMC2022
ArticleDMT

The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Reckweg JT, Uthaug MV, Szabo A +4

Europe PMC2022
ArticleMescaline

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.

Uthaug MV, Davis AK, Haas TF +5

Europe PMC2022
ArticleMescaline

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes.

Agin-Liebes G, Haas TF, Lancelotta R +3

Europe PMC2021
ArticleDMT

Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.

Sherwood AM, Claveau R, Lancelotta R +2

Europe PMC2020
ArticlePsilocybin

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.

Luoma JB, Chwyl C, Bathje GJ +2

Europe PMC2020
ArticleDMT

Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.

Uthaug MV, Lancelotta R, Szabo A +3

Europe PMC2020
ArticleDMT

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.

Uthaug MV, Lancelotta R, van Oorsouw K +10

Europe PMC2019
ArticleDMT

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

Davis AK, So S, Lancelotta R +2

Europe PMC2019
ArticlePsilocybin

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.

Barsuglia J, Davis AK, Palmer R +6

Europe PMC2018
ArticleDMT

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Davis AK, Barsuglia JP, Lancelotta R +2

Europe PMC2018